Evidence map›Paper›PMID 29230669›Full record

ArticleJournal of neuro-oncology2018

P21

Wei Dong, Jianhua Li, Qian Liu, Chunhui Liu, Chuzhong Li, Guidong Song, Haibo Zhu, Hua Gao, Yazhuo Zhang

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. DNA Methylation in Pituitary Adenomas: A Scoping Review.International journal of molecular sciences · 2025
    Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Wei DongKey Laboratory of Central Nervous System Injury Research, Beijing Neurosurgical Institute, Capital Medical University, Tiantanxili 6#, Beijing, 100050, China.
Jianhua LiDepartment of Neurosurgery, Binzhou People's Hospital, Binzhou, Shandong, China.
Qian LiuKey Laboratory of Central Nervous System Injury Research, Beijing Neurosurgical Institute, Capital Medical University, Tiantanxili 6#, Beijing, 100050, China.
Chunhui LiuKey Laboratory of Central Nervous System Injury Research, Beijing Neurosurgical Institute, Capital Medical University, Tiantanxili 6#, Beijing, 100050, China.
Chuzhong LiKey Laboratory of Central Nervous System Injury Research, Beijing Neurosurgical Institute, Capital Medical University, Tiantanxili 6#, Beijing, 100050, China.
Guidong SongKey Laboratory of Central Nervous System Injury Research, Beijing Neurosurgical Institute, Capital Medical University, Tiantanxili 6#, Beijing, 100050, China.
Haibo ZhuKey Laboratory of Central Nervous System Injury Research, Beijing Neurosurgical Institute, Capital Medical University, Tiantanxili 6#, Beijing, 100050, China.
Hua GaoKey Laboratory of Central Nervous System Injury Research, Beijing Neurosurgical Institute, Capital Medical University, Tiantanxili 6#, Beijing, 100050, China.
Yazhuo ZhangKey Laboratory of Central Nervous System Injury Research, Beijing Neurosurgical Institute, Capital Medical University, Tiantanxili 6#, Beijing, 100050, China. zyz2004520@yeah.net.ORCID http://orcid.org/0000-0002-8583-2580
Capital Medical University · CNBinzhou People's Hospital · CN

Funding

Beijing high level program (2015-3-040) and the National Natural Science Foundation of China 81502154Beijing Natural Science Foundation of China 7162035the National High Technology Research and Development Program of China (863 Program) 2015AA020504
6 · The paper itself

Abstract

Cell cycle control can prevent excessive proliferative response in the pituitary homeostasis. Cyclin dependent kinases (Cdks) are modulated by cyclins or Cdk inhibitors, such as p21 and p27, which can regulate cell cycle progression from the G1 to S phases. This study was conducted to evaluate the levels and the promoter region methylation status of p21 and p27 in prolactinomas (PRL) and analyze their association with clinicopathologic features. We found high-p21 level cases were featured by 5/23 and H-scores 142.3 ± 23.7 in invasive-PRL specimens, and 19/25 and 221.3 ± 45.4 in non-invasive specimens (x

Indexed as

DNA MethylationAdolescentAdultBiomarkers, TumorCyclin-Dependent Kinase Inhibitor p21Cyclin-Dependent Kinase Inhibitor p27FemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedNeoplasm InvasivenessPituitary NeoplasmsProlactinomaPromoter Regions, GeneticRNA, MessengerBiomarkers, TumorCyclin-Dependent Kinase Inhibitor p21Cyclin-Dependent Kinase Inhibitor p27RNA, MessengerInvasionMethylationP21Waf1/Cip1P27Kip1Prolactinomas

Identifiers

PMID29230669
OpenAlexW2773832061

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.